Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Active-controlled, Parallel, Dose-finding Phase 2 Clinical Study to Evaluate the Efficacy and Safety of SPH3127 Tablets in the Treatment of Diabetic Kidney Disease

NCT05593575 is registered in ClinicalTrials.gov with Shanghai Pharmaceuticals Holding Co., Ltd as lead sponsor.

NCT NCT05593575
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05593575 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel, Dose-finding Phase 2 Clinical Study to Evaluate the Efficacy and Safety of SPH3127 Tablets in the Treatment of Diabetic Kidney Disease
Lead sponsor
Shanghai Pharmaceuticals Holding Co., Ltd
Phase
Phase 2
Overall status
Completed
Start date
March 22, 2023
Completion date
December 31, 2024
Enrollment
305 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic kidney disease